Sökning: onr:"swepub:oai:gup.ub.gu.se/60279" >
Growth hormone redu...
Growth hormone reduces inflammation in postmenopausal women with abdominal obesity: a 12-month, randomized, placebo-controlled trial.
-
- Franco Ramos, Celina, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
-
- Andersson, Björn, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
- Lönn, Lars, 1956 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
visa fler...
-
- Bengtsson, Bengt-Åke, 1944 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
- Svensson, Johan, 1964 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
- Johannsson, Gudmundur, 1960 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine
-
visa färre...
-
(creator_code:org_t)
- The Endocrine Society, 2007
- 2007
- Engelska.
-
Ingår i: The Journal of clinical endocrinology and metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 92:7, s. 2644-7
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- CONTEXT: Abdominal obesity is associated with low GH secretion, elevated circulating markers of inflammation, and increased risk of cardiovascular disease. OBJECTIVE: The objective was to study the effect of GH treatment on inflammatory markers and vascular adhesion molecules in postmenopausal women with abdominal obesity. DESIGN: Forty women aged 51-63 yr received GH (0.67 mg/d) in a randomized, double-blind, placebo-controlled, 12-month trial. Measurements of inflammatory markers [highly sensitive C-reactive protein (CRP), IL-6, and amyloid polypeptideA] and markers of endothelial dysfunction (soluble E-selectin, vascular adhesion molecule-1, intercellular molecule-1, and matrix metalloproteinase-9) were performed at baseline and after 6 and 12 months of treatment. RESULTS: After 12 months, the mean IGF sd score was 0.9 +/- 1.5 and -0.8 +/- 0.6 in the GH and placebo groups, respectively. GH treatment reduced CRP and IL-6 levels compared with placebo (P = 0.03 and P = 0.05, respectively), whereas the markers of endothelial dysfunction were unaffected. Within the GH-treated group, a reduction was shown in CRP (4.3 +/- 4 to 3.0 +/- 3 mg/liter; P < 0.05) and in IL-6 (4.4 +/- 2 to 3.3 +/- 2 ng/liter; P < 0.01). In the GH-treated group, the decrease in CRP and IL-6 correlated with a reduction in visceral adipose tissue (r = 0.7, P < 0.001 and r = 0.5, P < 0.05, respectively). CONCLUSION: GH treatment in postmenopausal women with abdominal obesity reduced serum markers of systemic inflammation. Circulating markers of endothelial dysfunction were unaffected by treatment.
Nyckelord
- Abdominal Fat
- Aged
- C-Reactive Protein
- metabolism
- Endothelium
- Vascular
- drug effects
- immunology
- Female
- Human Growth Hormone
- therapeutic use
- Humans
- Inflammation
- blood
- drug therapy
- Interleukin-6
- blood
- Middle Aged
- Obesity
- drug therapy
- immunology
- metabolism
- Placebos
- Postmenopause
- Serum Amyloid A Protein
- metabolism
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas